OrthoPediatrics Corp. announced that its partner iotaMotion’s iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children four years of age and older, marking the first open‑platform robotic device approved for cochlear implant surgery in this age group.
The clearance expands the company’s Enabling Technologies division beyond its core orthopedic portfolio into the pediatric ENT market. Cincinnati Children’s Hospital became the first dedicated pediatric center to adopt the system, and more than 35 leading cochlear‑implant centers nationwide have already incorporated the technology.
The iotaSOFT® system offers robotic‑assisted insertion that controls speed and consistency, aiming to reduce surgical variability and preserve delicate intracochlear structures. The technology is positioned to address a market where fewer than 5% of eligible children receive implants, creating a sizable opportunity for a first‑mover advantage.
OrthoPediatrics’ financial performance in 2025 showed record revenue of $236.1 million, up 15% from the prior year, but the company continued to post a negative net margin of about 20% and an earnings‑per‑share loss of $1.95. Guidance for 2026 projects revenue of $262–$266 million, an 11–13% increase, while the company maintains a capital‑light model for the new partnership.
CEO David Bailey emphasized that the clearance “leverages our pediatric‑first expertise beyond orthopedics and deepens our impact in the ENT space with a technology that can improve surgical outcomes.” He added that the partnership aligns with the company’s strategy to expand into adjacent pediatric care segments while preserving a cash‑friendly business model.
Analysts view the approval as a strategic diversification that could open new revenue streams, but they remain cautious about the company’s profitability trajectory. The market has noted the company’s ongoing negative margins and the limited size of the cochlear‑implant market relative to its overall portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.